Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.news

Press Release: Dupixent® FDA approved as first and only treatment indicated for…

Dupixent ®FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for which Dupixent is approved in children this young, underscoring the commitment to bringing therapies to young patients with significant unmet needs EoE is...

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; January 25, 2024 –Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 5,281 restricted stock units and 5,468 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on...

South Korea Wheelchair Market Size to Surpass US$ 2.54 Billion by 2030 |…

Secondly, favorable initiatives by the South Korean government are also driving market growth. The government has implemented various policies and regulations to enhance accessibility and mobility for individuals with disabilities. For instance, the Korean Disability Act ensures equal rights and opportunities for disabled individuals. These initiatives have led to increased funding for wheelchair distribution and rehabilitation centers, further boosting the market. Secondly, favorable...

Global Sacroiliac Joint Fusion Market to Reach US$ 1,525.1 Million by 2030…

Market Snapshot: Market Snapshot: Key Market Takeaways: Market Trends: One of the key trends in the Global Sacroiliac Joint Fusion Market is the growing adoption of minimally invasive procedures. Minimally invasive sacroiliac joint fusion surgeries offer numerous advantages over traditional open surgeries, such as smaller incisions, reduced pain, faster recovery time, and lower risk of complications. As a result, an increasing number of healthcare providers and patients are...

Renovaro Biosciences Announces Results of Special Meeting of Shareholders

All of the matters put forward before the Company's shareholders for consideration and approval, as set out in the Company's definitive proxy statement dated January 3, 2024, were approved by the requisite number of votes cast at the meeting.For complete results on all matters voted on at the meeting, please consult the Company's Form 8-K which will be filed on EDGAR at www.sec.gov/edgar. ABOUT THE COMPANYRenovaro has developed advanced cell, gene, and immunotherapy platforms...

Increase of 2023 revenue at €10.5 million

Press release Ecully, January 25, 2024 – 6.00 p.m. 2023 revenue of €10.5 millionIn thousands of eurosUnaudited data 20232022% change Q1 revenue2,399 1,342 +79%Q2 revenue3,034 1,770 +71%Q3 revenue2,077 2,249 -8%Q4 revenue3,009 2,071 +45% Full-year revenue 10,519 7,432* +42%* 2022 revenue includes the share of revenue derived from Spine Innovations since its consolidation on July 21, 2022, i...

European Bioplastics Calls for Action to Accelerate Biopolymers Industrial…

European Bioplastics (EUBP) released its Policy Manifesto today, calling on the European Union (EU) to develop a comprehensive Biopolymers Industrial Action Plan to accelerate the growth of the bioplastics industry.EUBP believes that an actionable EU Bioeconomy Strategy, supporting a strong biopolymers industrial base, should be among the most important elements of the next EU policy cycle EUBP calls on the future Commission and co-legislators to develop a Biopolymers Industrial Action...

Spinal Implants Market Worth $14.3 Billion | MarketsandMarkets™

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=712 Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=712 Browse in-depth TOC on "Spinal Implants Market" 359 - Tables 45 - Figures 335 - Pages Spinal Implants Market Scope: Non-Fusion Devices segment to register a significant growth rate over the forecast period of 2022-2028. Based on the product, the spinal implants market is...

Critical Path Institute Appoints Dr. Klaus Romero as New CEO and Promotes Cécile…

M. Wainwright Fishburn, Jr., Chairman of C-Path's Board, commented on the appointment: "Dr. Romero's outstanding expertise and leadership have been instrumental in our journey to create and implement groundbreaking scientific and regulatory pathways. His strategic vision aligns perfectly with C-Path's mission of accelerating the development of novel therapies. We are confident in his capacity to propel the organization forward in its next phase of global impact and pioneering…

How Clinical Whole Exome Sequencing Helped 3-Year-Old Kosta - Patient's Voice

A breakthrough came with BGI Genomics Clinical Whole Exome Sequencing (cWES) test conducted at the Ginekalix laboratory in Skopje, Macedonia. cWES is a type of genetic test that sequences, or reads, the exons or coding regions of the genes in a person's genome. These regions are responsible for producing proteins and are often where genetic disorders are found. Kosta was identified with autosomal recessive spinocerebellar ataxia-2 (ARCA2), caused by a PMPCA gene mutation. This rare condition led…

Esaote unveils its new brand identity at 2024 Worldwide Sales & Marketing…

Together with the extraordinary renewal in all areas – products, infrastructure, business and organisational models – that has occurred in these last few years of constant growth, Esaote has decided to revise its brand identity to align with its vision, mission and core values. Together with the extraordinaryrenewal in all areas – products, infrastructure, business and organisational models– that has occurred in these last few years of constant growth,Esaote has decided to revise its...

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the…

Under the terms of the agreement, GSSA will receive from Jiangsu Alphamab and 3D Medicines, an exclusive license to develop, register, commercialize, Envafolimab for the oncology indication in the Territory. Jiangsu Alphamab will be the exclusive supplier of the product. 3D Medicines retains the right to develop and commercialize Envafolimab for any purpose outside the Territory. The Licensors will receive a low double digit Million US Dollar amount up to launch, additional triple digit Million…

LifeArc Ventures - six new investments, portfolio progress and an expanding…

LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space. We also participated in several follow-on rounds across our portfolio. LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space. We also participated in several follow-on rounds across our portfolio. We have expanded our investment team, adding two...

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the…

Under the terms of the agreement, GSSA will receive from Jiangsu Alphamab and 3D Medicines, an exclusive license to develop, register, commercialize, Envafolimab for the oncology indication in the Territory. Jiangsu Alphamab will be the exclusive supplier of the product. 3D Medicines retains the right to develop and commercialize Envafolimab for any purpose outside the Territory. The Licensors will receive a low double digit Million US Dollar amount up to launch, additional triple digit Million…

Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with…

As an oral therapy, danegaptide targets the core pathological events in DR, including cell-cell uncoupling, apoptotic vascular cell death and vascular leakage, at earlier stages of disease progression. As an oral therapy, danegaptide targets the core pathological events in DR, including cell-cell uncoupling, apoptotic vascular cell death and vascular leakage, at earlier stages of disease progression. With safety data derived from over 500 clinical trial participants, robust toxicology data,...

Welcome to SciBase Capital Markets Day 2024

During SciBase's Capital Markets Day, Pia Renaudin, who assumed the role of CEO in October 2023, will provide insights into SciBase's future trajectory, and unveil an updated strategic outlook, and long-term strategic goals. The presentations will underscore the company's focus on the USA and shed light on SciBase's ongoing expansion into promising new markets. During SciBase's Capital Markets Day,Pia Renaudin, who assumed the role of CEO inOctober 2023, will provide insights into...

Nicox Provides Fourth Quarter 2023 Financial and Business Highlights

Press ReleaseNicox Provides Fourth Quarter 2023 Financial and Business HighlightsNCX 470 Phase 3 Denali clinical trial 75% randomizedNet revenue €1.3 million for fourth quarter 2023 and €4.2 million for the full year 2023, an increase of 29% compared to the full year 2022Cash of €11.9 million on December 31, 2023The Company is financed to June 2024, based on the development of NCX 470 alone, and continues to seek opportunities to increase the cash...

Essity: Year-end Report 2023

CEO'S COMMENTS CEO'S COMMENTS Highest profit ever and strong platform for growth Essity reached a net sale in 2023 ofSEK 147bnand adjusted EBITA ofSEK 18.9bn, excluding Vinda. Having offset cost inflation through price increases and improved the structural profitability, we increased focus during the fourth quarter on volume growth and market shares. The company Isola Castle Ltd has announced that it will make a pre-conditional public offer for the shares in Vinda, entailing a...

Groupe Casino: Disposal of group Casino's stake in Éxito Group

Global mRNA-based Vaccines and Therapeutics Market is Projected to Grow…

ONWARD® ARC Therapy™ Highlighted at 2024 Annual Meeting of the North American…

Relapsing/Refractory Multiple Myeloma Market to Observe Stupendous Growth by…

Ceva Santé Animale acquires Scout Bio, paving the way for groundbreaking…

The Europe Laboratory Information Management System (LIMS) Market to Reach…

Press Release: Dupixent® FDA approved as first and only treatment indicated for…

Grant of Restricted Stock Units and Warrants to Employees in Genmab

South Korea Wheelchair Market Size to Surpass US$ 2.54 Billion by 2030 |…

Global Sacroiliac Joint Fusion Market to Reach US$ 1,525.1 Million by 2030…

Renovaro Biosciences Announces Results of Special Meeting of Shareholders

Increase of 2023 revenue at €10.5 million

European Bioplastics Calls for Action to Accelerate Biopolymers Industrial…

Spinal Implants Market Worth $14.3 Billion | MarketsandMarkets™

Critical Path Institute Appoints Dr. Klaus Romero as New CEO and Promotes Cécile…

How Clinical Whole Exome Sequencing Helped 3-Year-Old Kosta - Patient's Voice

Esaote unveils its new brand identity at 2024 Worldwide Sales & Marketing…

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the…

LifeArc Ventures - six new investments, portfolio progress and an expanding…

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the…

Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with…

Welcome to SciBase Capital Markets Day 2024

Nicox Provides Fourth Quarter 2023 Financial and Business Highlights

Essity: Year-end Report 2023